Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

NCT07095127 is registered in ClinicalTrials.gov with Nuvig Therapeutics, Inc. as lead sponsor.

NCT NCT07095127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07095127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia
Lead sponsor
Nuvig Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2025
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)